ArticleDiscover oncology2025
NCAPG2 is a diagnostic biomarker associated with immune infiltration in cholangiocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- NCAPG reprograms glycolytic and lipid metabolism by sustaining glycerophospholipid flux in small-cell lung cancer.Molecular and cellular biochemistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundCholangiocarcinoma (CHOL) is the second largest malignant tumor in the bile duct, only after primary liver cancer. Their high invasiveness can lead to poor prognosis. Over the past decade, research on CHOL has been ongoing, but there have been no breakthrough advancements. According to the literature, NCAPG2 is associated with the progression of various tumors, but its relevant role and value in CHOL have not been extensively studied.
methodsWe studied the expression of NCAPG2 in CHOL and its clinical and pathological diagnostic value based on TCGA and GEO datasets. We evaluated the association between NCAPG2 and immune-related cells in CHOL using the TISIDB database.
resultsWe found that NCAPG2 has a higher expression level in CHOL and diagnostic significance in patients with CHOL. Additionally, we observed a correlation between immune cell infiltration and NCAPG2 levels in CHOL. Furthermore, NCAPG2 and its co-expressed genes were predominantly concentrated in ATP-dependent activity, DNA-related functions, and DNA helicase activity. The expression level of NCAPG2 is intricately linked to the pathological classification of CHOL.
conclusionCurrent research indicates that NCAPG2 may provide effective assistance for the early diagnosis and pathological classification of CHOL, potentially regulating the immune microenvironment and thereby influencing the occurrence and progress of CHOL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.